The goal of this study is to provide evidence for the safety and immunogenicity of the 2025-2026 formulation in individuals 12 through 64 years of age with at least 1 underlying health condition that puts them at high risk for severe outcomes from COVID-19, and individuals ≥65 years of age.
- Seeking volunteers ages 12 -17 years old; and adults 18+ years old.
- Two in-person clinic visits one month a part.
If interested, follow this link to sign up for the study.
- Compensation provided for time and travel.
Sponsor(s)
Pfizer Inc.
Principal Investigator(s)
Dr. David Diemert
Contact Phone Number
Request Information